

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-11. (cancelled)

12. (previously presented) A fusion protein displayed on a yeast cell surface, the amino acid sequence of said fusion protein comprising a polypeptide sequence joined at its N-terminus to the C-terminus of an agglutinin subunit Aga2p sequence, said Aga2p being joined by two disulfide bonds to an agglutinin subunit Aga1p on said yeast cell surface, wherein said amino acid sequence further includes a first epitope tag sequence between said Aga2p and polypeptide sequence wherein said amino acid sequence further includes a second epitope tag sequence joined to the C-terminus of said polypeptide sequence.

13. (original) The fusion protein of claim 12 wherein a label is bound to said second epitope tag.

14. (previously presented) A fusion protein displayed on a yeast cell surface, the amino acid sequence of said fusion protein consisting of a polypeptide sequence joined at its N-terminus to the C-terminus of an agglutinin subunit Aga2p sequence, said Aga2p being joined by two disulfide bonds to an agglutinin subunit Aga1p on said yeast cell surface wherein a label is bound to said polypeptide.

15-16. (cancelled)

17. (previously presented) A fusion protein displayed on a yeast cell surface, the amino acid sequence of said fusion protein consisting of a polypeptide sequence joined at its N-terminus to the C-terminus of an agglutinin subunit Aga2p sequence, said Aga2p being joined by two disulfide bonds to an agglutinin subunit Aga1p on said yeast cell surface wherein said polypeptide is a ligand binding polypeptide wherein said ligand binding polypeptide is chosen from the group consisting of functional antibodies and cell surface receptors and fragments thereof wherein said polypeptide is an anti-T cell receptor or a fragment thereof.
18. (previously presented) A fusion protein displayed on a yeast cell surface, the amino acid sequence of said fusion protein consisting of a polypeptide sequence joined at its N-terminus to the C-terminus of an agglutinin subunit Aga2p sequence, said Aga2p being joined by two disulfide bonds to an agglutinin subunit Aga1p on said yeast cell surface wherein said polypeptide is a ligand binding polypeptide wherein said ligand binding polypeptide is chosen from the group consisting of functional antibodies and cell surface receptors and fragments thereof wherein said antibody or fragment thereof is an anti-T cell fragment chosen from the group consisting of SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, and SEQ ID NO:24.
19. (previously presented) A fusion protein displayed on a yeast cell surface, the amino acid sequence of said fusion protein consisting of a polypeptide sequence joined at its N-terminus to the C-terminus of an agglutinin subunit Aga2p sequence, said Aga2p being joined by two disulfide bonds to an agglutinin subunit Aga1p on said yeast cell surface wherein said polypeptide is a ligand binding polypeptide wherein said ligand binding polypeptide is chosen from the group consisting of functional antibodies and cell surface receptors and fragments thereof wherein said polypeptide is a T cell receptor or fragment thereof.

20. (original) The fusion protein of claim 19 wherein said T cell receptor or fragment thereof has been mutagenized.

21. (original) The fusion protein of claim 20 wherein said mutant T cell receptor or fragment thereof is SEQ ID NO:24.

22-23. (cancelled)

24. (previously presented) A yeast cell displaying a fusion protein having an amino acid sequence consisting of a ligand binding polypeptide sequence joined at its N-terminus to the C-terminus of an agglutinin subunit Aga2p sequence, said Aga2p being joined by two disulfide bonds to an agglutinin subunit Aga1p on said yeast cell surface said polypeptide sequence is a mutant of a related wild-type polypeptide.

25-26. (cancelled)

27. (original) In a yeast cell displaying a fusion protein, the improvement comprising: said fusion protein containing a mutant ligand binding protein joined at its N-terminus to the C-terminus of a first epitope tag sequence, the N-terminus of said first epitope tag sequence joined to C-terminus of an agglutinin subunit Aga2p sequence, the mutant ligand binding protein being joined at its C-terminus to a second epitope tag, said Aga2p being joined by two disulfide bonds to an agglutinin subunit Aga1p on said yeast cell surface.

28. (original) In a yeast cell displaying a fusion protein, the improvement comprising: said fusion protein containing a mutated T cell binding protein joined at its N-terminus to the C-terminus of a first epitope tag sequence, the N-terminus of said first epitope tag sequence joined to C-terminus of an agglutinin subunit Aga2p

sequence, the T cell binding protein sequence being joined at its C-terminus to a second epitope tag, said Aga2p being joined by two disulfide bonds to an agglutinin subunit Aga1p on said yeast cell surface.

29. (original) In a yeast cell displaying a fusion protein, the improvement comprising: said fusion protein containing a mutated antibody or fragment thereof capable of antigen-specific binding joined at its N-terminus to the C-terminus of a first epitope tag sequence, the N-terminus of said first epitope tag sequence joined to C-terminus of an agglutinin subunit Aga2p sequence, the antibody or fragment being joined at its C-terminus to a second epitope tag, said Aga2p being joined by two disulfide bonds to an agglutinin subunit Aga1p on said yeast cell surface.

30-97.(cancelled)